These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 12694871)

  • 1. Recognition of DNA modified by antitumor cisplatin by "latent" and "active" protein p53.
    Fojta M; Pivonkova H; Brazdova M; Kovarova L; Palecek E; Pospisilova S; Vojtesek B; Kasparkova J; Brabec V
    Biochem Pharmacol; 2003 Apr; 65(8):1305-16. PubMed ID: 12694871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different recognition of DNA modified by aatitumor cisplatin and its clinically ineffective trans isomer by tumor suppressor protein p53.
    Kasparkova J; Pospisilova S; Brabec V
    J Biol Chem; 2001 May; 276(19):16064-9. PubMed ID: 11279186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 binds to cisplatin-damaged DNA.
    Wetzel CC; Berberich SJ
    Biochim Biophys Acta; 2001 Feb; 1517(3):392-7. PubMed ID: 11342217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recognition of cisplatin-damaged DNA by p53 protein: critical role of the p53 C-terminal domain.
    Pivonková H; Brázdová M; Kaspárková J; Brabec V; Fojta M
    Biochem Biophys Res Commun; 2006 Jan; 339(2):477-84. PubMed ID: 16300733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of the DNA-binding ability of latent p53 protein by protein kinase C is abolished by protein kinase CK2.
    Pospísilová S; Brázda V; Kucharíková K; Luciani MG; Hupp TR; Skládal P; Palecek E; Vojtesek B
    Biochem J; 2004 Mar; 378(Pt 3):939-47. PubMed ID: 14640983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of p53 "latency" and "activation" by fluorescence correlation spectroscopy. Evidence for different modes of high affinity DNA binding.
    Wölcke J; Reimann M; Klumpp M; Göhler T; Kim E; Deppert W
    J Biol Chem; 2003 Aug; 278(35):32587-95. PubMed ID: 12813031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific modulation of p53 binding to consensus sequence within supercoiled DNA by monoclonal antibodies.
    Brázda V; Paleĉek J; Pospísilová S; Vojtêsek B; Paleĉek E
    Biochem Biophys Res Commun; 2000 Jan; 267(3):934-9. PubMed ID: 10673394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p53 Latency. C-terminal domain prevents binding of p53 core to target but not to nonspecific DNA sequences.
    Yakovleva T; Pramanik A; Kawasaki T; Tan-No K; Gileva I; Lindegren H; Langel U; Ekstrom TJ; Rigler R; Terenius L; Bakalkin G
    J Biol Chem; 2001 May; 276(19):15650-8. PubMed ID: 11279079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allosteric regulation of the thermostability and DNA binding activity of human p53 by specific interacting proteins. CRC Cell Transformation Group.
    Hansen S; Hupp TR; Lane DP
    J Biol Chem; 1996 Feb; 271(7):3917-24. PubMed ID: 8632013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of DNA binding of p53 by its C-terminal domain.
    Weinberg RL; Freund SM; Veprintsev DB; Bycroft M; Fersht AR
    J Mol Biol; 2004 Sep; 342(3):801-11. PubMed ID: 15342238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of mutant p53 temperature-sensitive DNA binding.
    Friedlander P; Legros Y; Soussi T; Prives C
    J Biol Chem; 1996 Oct; 271(41):25468-78. PubMed ID: 8810317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential recognition by the tumor suppressor protein p53 of DNA modified by the novel antitumor trinuclear platinum drug BBR3464 and cisplatin.
    Kasparkova J; Fojta M; Farrell N; Brabec V
    Nucleic Acids Res; 2004; 32(18):5546-52. PubMed ID: 15486204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of the sequence-specific DNA binding function of p53 by protein kinase C and protein phosphatases.
    Takenaka I; Morin F; Seizinger BR; Kley N
    J Biol Chem; 1995 Mar; 270(10):5405-11. PubMed ID: 7534296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor suppressor protein p53 binds preferentially to supercoiled DNA.
    Palecek E; Vlk D; Stanková V; Brázda V; Vojtesek B; Hupp TR; Schaper A; Jovin TM
    Oncogene; 1997 Oct; 15(18):2201-9. PubMed ID: 9393978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA modification with cisplatin affects sequence-specific DNA binding of p53 and p73 proteins in a target site-dependent manner.
    Pivonková H; Pecinka P; Cesková P; Fojta M
    FEBS J; 2006 Oct; 273(20):4693-706. PubMed ID: 16981908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of p53 sequence-specific DNA binding by short single strands of DNA requires the p53 C-terminus.
    Jayaraman J; Prives C
    Cell; 1995 Jun; 81(7):1021-9. PubMed ID: 7600571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA binding activities of p53 protein following cisplatin damage of ovarian cells.
    Wetzel CC; Berberich SJ
    Oncol Res; 1998; 10(3):151-61. PubMed ID: 9700726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Precise characterisation of monoclonal antibodies to the C-terminal region of p53 protein using the PEPSCAN ELISA technique and a new non-radioactive gel shift assay.
    Pospísilová S; Brázda V; Amrichová J; Kamermeierová R; Palecek E; Vojtesek B
    J Immunol Methods; 2000 Apr; 237(1-2):51-64. PubMed ID: 10725451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A single HMG domain in high-mobility group 1 protein binds to DNAs as small as 20 base pairs containing the major cisplatin adduct.
    Chow CS; Barnes CM; Lippard SJ
    Biochemistry; 1995 Mar; 34(9):2956-64. PubMed ID: 7893709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein interactions at the carboxyl terminus of p53 result in the induction of its in vitro transactivation potential.
    Mundt M; Hupp T; Fritsche M; Merkle C; Hansen S; Lane D; Groner B
    Oncogene; 1997 Jul; 15(2):237-44. PubMed ID: 9244359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.